金沙(8888js-官方JS认证)-Made in China

Jason Zhu

Executive Director
Chief Executive Officer
Chief Financial Officer

Mr. Jason Zhu is the Executive Director, Chief Executive Officer, and Chief Financial Officer of Henlius. Jason has more than 20 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. Jason holds a bachelor degree in Clinical Medicine form Shanghai Medical College of Fudan University and an EMBA degree from CKGSB.
Wei Huang

President

Ms. Wei Huang, President, is in charge of the Global Manufacturing Engineering Technology Department, the Global Quality Operations Department and the wholly-owned subsidiary, Aton (Shanghai) Biotech Co., Ltd., ("Aton Biotech"), responsible for the production and supply of the Company's clinical and commercial products, the design and implementation of engineering projects, the continuous improvement and optimization of production capacity and the business decisions of Aton Biotech. Ms. Huang holds Bachelor degree from East China University of Science and Technology in Biochemical Engineering, Master degree from University of Maryland in Chemical and Biochemical Engineering. Prior to joining Henlius, Ms. Huang has Senior management and leadership experience in pharmaceutical and biotechnology industry spanning over twenty-five years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation.
James Guo

SVP

Mr. James Guo, Senior Vice President, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University. He has previously served as research manager and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd. and Shanghai Chemo Wanbang Biopharma Co., Ltd. James is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. He has been involved in the development of a Category II new drug, the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. He was awarded Shanghai Labor Medal, Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. Under his leadership, Henlius was awarded 2021 National Worker Pioneer, 2021 Shanghai Worker Pioneer, 2020 Shanghai Model Group and 2019 Shanghai Worker Pioneer.
In addition, he is the member of the Pharmaceutical Innovation Investment Specialty Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), the vice-chairman of Shanghai Biopharmaceutics Industry Association (SBIA) and the member of the 9th council of Shanghai Pharmaceutical Profession Association (SPPA).
Kurt Yu

SVP
Chief Commercial Officer

Mr. Kurt Yu, Senior Vice President and Chief Commercial Officer, is in charge of the Marketing and Commercial Operations Department and the Medical Affairs Department, responsible for the commercial operations. Prior to joining Henlius, Mr. Yu has over 20 years’ experience in sales and central marketing management (for Glaxo Wellcome, Roche and Amgen) with different roles including medical representative, product manager, district sales manager, marketing manager, and marketing director/ head. He has rich experience in portfolio management, marketing strategy development, new product launch etc.

Mr. Yu graduated from Shanghai Medical University with bachelor degree in pharmaceutical chemistry. Then he obtained the EMBA degree from Fudan University.
Ping Cao

SVP
Chief Business Development Officer

Ms. Ping Cao, Senior Vice President and Chief Business Development Officer, is in charge of the Business Development Department, responsible for the Company's business cooperation with external partners, including licensing in and out, authorization, partnership alliance, merger and acquisition. Ms. Cao graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She evaluated, negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.
Simon Hsu

SVP
Chief Technology Officer

Dr. Simon Hsu holds PhD degree from Purdue University in Biochemical Engineering, Master degree from Ohio State University in Biochemical Engineering, and Bachelor degree from National Tsing Hua University in Chemical Engineering. Dr. Simon Hsu has over 2 8 years of management and research experience in the pharmaceutical industry . He has directed and successfully managed more than 25 antibody and recombinant protein projects of technology transfer, scale up and process validation up to 40,000 L Prior to joining Henlius, he served for leading enterprise in pharmaceuticals ind ustry, such as GenSci , HuiGene Therapeutics , Henlius, Pieris, Shire, Bristol Myers Squibb MedImmune AstraZeneca )), Alexion AstraZeneca etc . Dr. Simon Hsu has extensive experience and technology in process development, production, quality control, project management, international registration, licensing applications, clinical to market commercialization, and continuous bioprocess etc.
Jessie Li

VP
Chief Human Resource Officer

Ms. Jessie Li, Vice President and Chief Human Resource Officer, is responsible for overall HR strategy, organization development, talent strategy. Ms. Jessie LI brings with her over 20 years of HR management experiences, and prior to joining Henlius, she worked in TCCP, Astra Zeneca, De Lage Landen, Kodak Healthgroup/Carestream as HRVP, Executive HR Director, Head of China HR. Ms. Jessie LI holds Bachelor degree from Shandong Finance University in International Finance in 1998, and MBA from Shanghai University of Finance and Economics – Webster University in 2002
Miaojie Chen

VP of Legal and Compliance Department

VP of Legal and Compliance in L&C Department. Miaojie will be responsible for the management and improvement of the legal and compliance system, supporting the planning and implementation of the sustainable development of company's legal and compliance, and supporting company's major projects.

Miaojie holds her Master degree from Illinois Institute of Technology, Chicago-Kent College of Law and Bachelor degree from East China University of Politics and Law. Miaojie was admitted to practice as an attorney at law in both New York State and PRC. And she has more than 17 years experiences both in top law firm and inhouse of pharmaceutical.

Prior to joining Henlius, Miaojie was the VP of Legal and general counsel in Eddingpharm Group, responsible for IPO, financing and investment, BD license-in & technology transfer deal, general corporate governance, and compliance.
Wallis Zeng

VP of Oncology Business Unit

Mr. Wallis Zeng, VP of Oncology Business Unit, graduated from Gannan Medical University, majoring in clinical medicine.

Mr. Zeng is responsible for the sales strategy development, establishing and leading the sales team to achieve the annual sales targets. Prior to joining Henlius, he served as regional sales manager at MSD, national sales director at Roche, general manager at Evergrande Health and sales director at AZ. So far, he has about 30 years’ working experience. Mr. Zeng has rich experience in sales strategy development and sales team management.
Ming Yang

VP of Immune-Oncology Business Unit

Mr. Ming Yang, Vice President of the Immune-Oncology Business Unit, is in charge of Sales Operations Department II, mainly responsible for the sales of immune-oncology products of the Company. Before joining Henlius, Ming served as important positions of many large multinational enterprises, such as Bristol-Myers Squibb, AstraZeneca, Roche, and Bayer. He has more than 20 years working experience in tumor immunity filed and led some blockbuster product launches in China such as Opdivo. Mr. Yang has rich experience in sales strategy development, commercial operation, and sales system establishment.
Yongqiang Shan

GM of Global Innovation Center

Dr. Yongqiang Shan, General Manager of Global Innovation Center, responsible for crafting and implementing strategy and operation of early research and development.

Dr. Yongqiang Shan has nearly 20 years’ experience in the research and development of new drugs, leading and participating in the research and development of many new lead and clinical candidate drugs, including small molecular compounds, monoclonal antibodies, antibody-drug conjugates (ADC), recombinant proteins, and small interfering nucleic acids. Prior to joining Henlius, he was Vice President of Translational Science and Head of Shanghai R&D Center of HighTide Therapeutics, Head of Discovery Biology of Hengrui Pharmaceutical, Head of Early Research and Development of Hua Medicine, and Scientist of China Novartis Institute for Biomedical Research. Before that, he worked in Chinese Academy of Medical Sciences, Peking University, and Chinese National Human Genome Center, Beijing, focusing on drug research and development. Dr. Yongqiang Shan holds Ph.D in Molecular Pharmacology from Tsinghua University and Peking Union Medical College, and Bachelor of Clinical Medicine and Master of Molecular Biology from China Medical University.
Arthur Sheng

GM of Global Strategy & PMO

The GM of Global Strategy & PMO. He is leading the company’s overall strategy development, including R&D strategy, portfolio management, manufacture & supply chain, commercialization and PMO. Prior to Henlius, he has been working for GSK, Roche Pharma, Roche diagnostic, MSD, Hizenpfizer and ZS Associates. With extensive experience in business strategy, medical affair, retail pharmacy & broad market, distribution and market access, key account management, business development and IVD.
Jing Li

GM of Global Product Development Department

Mr. Jing Li is the General Manager of Global Product Development Department, responsible for strategy planning and study operation for research product.
During over 15 years on clinical research, he has successfully launched the first biosimilar drug in China(HANLIKANG), the first EMA approved biologic product from China(HANQUYOU), and managed over 80 clinical trials, covering clinical phase 1 to Phase 4 trials.
Before joining Henlius, he worked for Hutchison, Roche, Covance and SPH. He has the master's degree of medicine from Tongji University.
Jin Li

Regulatory Affairs General Manager

Ms. Li Jin currently works at Shanghai Henlius Biothech. Inc. as Regulatory Affairs General Manager starting from Sep. 13th, 2021. She is responsible for leading RA team, developing regulatory strategy to ensure the product filing activities in China and global market.

Ms. Li Jin graduated from Beijing University of Chinese Medicine with a Bachelor’s degree in Traditional Chinese Medicine. She has about 22 years experience in regulatory affairs. Prior to joining Henlius, she held the key position in many different types of companies, including local and multi-national ones, for example Nuance, Mundi Pharma, Merck Serono, Amgen, MSD and China Grand Enterprises, etc. She also had 5 years medicine research experience in pharmaceutical R&D center. her ability to control different stages of different products are excellent due to previous experienced in various types of companies, including small molecular, biological and medical device products, etc. In addition, she has rich team management skill, especially on team building up and member development.
Jasmin Wang

General Manager of Quality

General Manager of Quality, Ms. Jasmin Wang, is responsible for the quality management of commercial manufacturing, clinical manufacturing and R&D. Ms. Wang graduated from East China University of Science and Technology and obtained a master of business administration degree from Fudan University. She has been in the biopharmaceutical industry for over 20 years and is mainly engaged in drug R&D, manufacturing and quality management.

Ms. Wang joined the Company in 2010 and successively served as QC, QA and manufacturing head. Ms. Wang has a deep understanding about drug regulations and antibody large-scale manufacturing and quality management. She plays a critical role in leading the GMP manufacturing and quality management of the Company.
Nancy Wang

Board Secretary

Ms. Nancy Wang, Board Secretary, is responsible for the organization of Shareholder General Meeting, Board Meeting and its committee meeting, and Supervisor Meeting as well as the information disclosure. She also takes charge of corporate branding and public relations. Previously, Ms. Wang has successively acted as Supervisor of the Marketing Department, Securities Affairs Representative and Manager of Public Affairs Department, Director of the Office of Board Secretary and Executive Director of Public Relations of the Company. Ms. Wang obtained her Bachelor’s degree in Bio-pharmacy from Nanjing Forestry University in 2010 and a Master’s degree in Biochemistry in 2013 from the same university.